Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.

被引：5
|
作者：
Wainberg, Zev A.
Shapiro, Geoffrey
Curigliano, Giuseppe
Leong, Stephen
Kristeleit, Rebecca Sophie
Maqueda, Maria Alsina
Britten, Carolyn D.
Milella, Michele
Middleton, Mark R.
Olszanski, Anthony J.
Vaishampayan, Ulka N.
Lopez-Martin, Jose A.
Gelmon, Karen A.
Brega, Nicoletta
Pierce, Kristen J.
Perea, Rachelle
Houk, Brett Edward
Pathan, Nuzhat
Gollerkeri, Ashwin
Razak, Albiruni R. A.
机构：
[1] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Ist Europeo Oncol, Milan, Italy
[4] Univ Colorado, Ctr Canc, Aurora, CO USA
[5] UCL, Inst Canc, London, England
[6] Hosp Valle De Hebron, Barcelona, Spain
[7] Med Univ S Carolina, Charleston, SC 29425 USA
[8] Regina Elena Inst Canc Res, Med Oncol A, Rome, Italy
[9] Oxford NIHR Biomed Res Ctr, Oxford, England
[10] Temple Hlth, Fox Chase Canc Ctr, Philadelphia, PA USA
[11] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[12] Hosp 12 Octubre, E-28041 Madrid, Spain
[13] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[14] Pfizer Italia, Milan, Italy
[15] Pfizer Oncol, Groton, CT USA
[16] Pfizer Worldwide Res & Dev, San Diego, CA USA
[17] Pfizer Inc, Carlsbad, CA USA
[18] Pfizer, San Diego, CA USA
[19] Pfizer BioTherapeut, Cambridge, MA USA
[20] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2590
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Biomarker evaluation in phase I clinical trials of selective PI3K and PI3k/mTOR inhibitors
    Spoerke, Jill
    Desai, Rupal
    Patel, Rajesh
    Fredrickson, Jill
    Wang, Yulei
    Levy, Gallia
    Gendreau, Steve
    Lauchle, Jennifer
    Derynck, Mika
    Raja, Rajiv
    Koeppen, Hartmut
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    CANCER RESEARCH, 2013, 73 (08)
  • [32] Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Spoerke, Jill
    O'Brien, Carol
    Wu, Jenny
    Desai, Rupal
    Patel, Rajesh
    Raja, Rajiv
    Koeppen, Hartmut
    Amler, Lukas
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    CANCER RESEARCH, 2012, 72
  • [33] In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458
    Albawardi, Alia
    Al Ayyan, Muna
    Al Bashir, Mohamed
    Souid, Abdul-Kader
    Almarzooqi, Saeeda
    CANCER CELL INTERNATIONAL, 2014, 14
  • [34] In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458
    Alia Albawardi
    Muna Al Ayyan
    Mohamed Al Bashir
    Abdul-Kader Souid
    Saeeda Almarzooqi
    Cancer Cell International, 14
  • [35] Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Nakanishi, Yoshito
    Spoerke, Jill M.
    Derynck, Mika
    Lauchle, Jennifer O.
    Koeppen, Hartmut
    Fredrickson, Jill
    Ware, Joseph
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [36] A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC).
    Tabernero, Josep
    Braga, Nicoletta
    Davis, Craig
    Gollerkeri, Ashwin
    Pierce, Kristen
    Suzuki, Mie
    Vermette, Jennifer
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells
    Shang, Xiaosong
    Na, Xinyu
    Wang, Lei
    Yang, Zhiqin
    Ren, Pengpeng
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [38] Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells
    Shang, Xiaosong
    Na, Xinyu
    Wang, Lei
    Yang, Zhiqin
    Ren, Pengpeng
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [39] PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
    Tarantelli, Chiara
    Gaudio, Eugenio
    Arribas, Alberto J.
    Kwee, Ivo
    Hillmann, Petra
    Rinaldi, Andrea
    Cascione, Luciano
    Spriano, Filippo
    Bernasconi, Elena
    Guidetti, Francesca
    Carrassa, Laura
    Pittau, Roberta Bordone
    Beaufils, Florent
    Ritschard, Reto
    Rageot, Denise
    Sele, Alexander
    Dossena, Barbara
    Rossi, Francesca Maria
    Zucchetto, Antonella
    Taborelli, Monica
    Gattei, Valter
    Rossi, Davide
    Stathis, Anastasios
    Stussi, Georg
    Broggini, Massimo
    Wymann, Matthias P.
    Wicki, Andreas
    Zucca, Emanuele
    Cmiljanovic, Vladimir
    Fabbro, Doriano
    Bertoni, Francesco
    CLINICAL CANCER RESEARCH, 2018, 24 (01) : 120 - 129
  • [40] A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer
    Giuseppe Curigliano
    Geoffrey I. Shapiro
    Rebecca S. Kristeleit
    Albiruni R. Abdul Razak
    Stephen Leong
    Maria Alsina
    Antonio Giordano
    Karen A. Gelmon
    Erica Stringer-Reasor
    Ulka N. Vaishampayan
    Mark Middleton
    Anthony J. Olszanski
    Hope S. Rugo
    Kenneth A. Kern
    Nuzhat Pathan
    Rachelle Perea
    Kristen J. Pierce
    Sarah C. Mutka
    Zev A. Wainberg
    British Journal of Cancer, 2023, 128 : 30 - 41
12345